AGILENT TECHNOLOGIES, INC. A
Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.
In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment. Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment. The remaining divisions in our former Life Sciences and Applied Markets segment which includes our gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy and vacuum divisions formed our new Applied Markets segment.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.95B | $6.51B | $6.83B | $6.85B | $6.32B | $5.34B | $5.16B | $4.91B | $4.47B | $4.20B |
| Cost of revenue | $3.31B | $2.98B | $3.37B | $3.13B | $2.91B | $2.50B | $2.36B | $2.23B | $2.07B | $2.00B |
| Gross profit | $3.64B | $3.54B | $3.46B | $3.72B | $3.41B | $2.84B | $2.81B | $2.68B | $2.40B | $2.20B |
| R&D | $455.0M | $479.0M | $481.0M | $467.0M | $441.0M | $495.0M | $404.0M | $387.0M | $341.0M | $329.0M |
| SG&A | $1.71B | $1.57B | $1.63B | $1.64B | $1.62B | $1.50B | $1.46B | $1.39B | $1.25B | $1.25B |
| Total operating expenses | $5.47B | $5.02B | $5.48B | $5.23B | $4.97B | $4.49B | $4.22B | $4.01B | $3.67B | $3.59B |
| Operating income | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B | $846.0M | $941.0M | $904.0M | $807.0M | $615.0M |
| Interest expense | $112.0M | $96.0M | $95.0M | $84.0M | $81.0M | $78.0M | $74.0M | $75.0M | $79.0M | $72.0M |
| Pre-tax income | $1.44B | $1.52B | $1.34B | $1.50B | $1.36B | $842.0M | $919.0M | $946.0M | $803.0M | $544.0M |
| Income tax | $132.0M | $232.0M | $99.0M | $250.0M | $150.0M | $123.0M | $152.0M | $630.0M | $119.0M | $82.0M |
| Net income | $1.30B | $1.29B | $1.24B | $1.25B | $1.21B | $719.0M | $1.07B | $316.0M | $684.0M | $462.0M |
| EPS, basic | 4.59 | 4.44 | 4.22 | 4.19 | 3.98 | 2.33 | 3.41 | 0.98 | 2.12 | 1.42 |
| EPS, diluted | 4.57 | 4.43 | 4.19 | 4.18 | 3.94 | 2.30 | 3.37 | 0.97 | 2.10 | 1.40 |
| Shares, diluted (wtd. avg.) | $285.0M | $291.0M | $296.0M | $300.0M | $307.0M | $312.0M | $318.0M | $325.0M | $326.0M | $329.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.79B | $1.33B | $1.59B | $1.06B | $1.49B | $1.45B | $1.39B | $2.25B | $2.69B | $2.29B |
| Receivables | $1.49B | $1.32B | $1.29B | $1.41B | $1.17B | $1.04B | $930.0M | $776.0M | $724.0M | $631.0M |
| Inventory | $1.02B | $972.0M | $1.03B | $1.04B | $830.0M | $720.0M | $679.0M | $638.0M | $575.0M | $533.0M |
| Total current assets | $4.59B | $3.96B | $4.19B | $3.78B | $3.80B | $3.42B | $3.19B | $3.85B | $4.17B | $3.63B |
| Property, plant and equipment | $2.02B | $1.78B | $1.27B | $1.10B | $945.0M | $845.0M | $850.0M | $822.0M | $757.0M | $639.0M |
| Goodwill | $4.47B | $4.48B | $3.96B | $3.95B | $3.98B | $3.60B | $3.59B | $2.97B | $2.61B | $2.52B |
| Other intangibles | $445.0M | $547.0M | $475.0M | $821.0M | $981.0M | $831.0M | $1.11B | $491.0M | $361.0M | $416.0M |
| Total assets | $12.73B | $11.85B | $10.76B | $10.53B | $10.71B | $9.63B | $9.45B | $8.54B | $8.43B | $7.79B |
| Accounts payable | $570.0M | $540.0M | $418.0M | $580.0M | $446.0M | $354.0M | $354.0M | $340.0M | $305.0M | $257.0M |
| Short-term debt | $304.0M | $45.0M | $0 | $36.0M | $0 | $75.0M | $616.0M | $0 | $210.0M | $0 |
| Total current liabilities | $2.35B | $1.90B | $1.60B | $1.86B | $1.71B | $1.47B | $2.08B | $1.17B | $1.26B | $945.0M |
| Long-term debt | $3.05B | $3.35B | $2.73B | $2.73B | $2.73B | $2.28B | $1.79B | $1.80B | $1.80B | $1.90B |
| Total liabilities | $5.99B | $5.95B | $4.92B | $5.23B | $5.32B | $4.75B | $4.70B | $3.97B | $3.59B | $3.55B |
| Retained earnings | $1.39B | $750.0M | $782.0M | $324.0M | $348.0M | $81.0M | -$18.0M | -$336.0M | -$126.0M | $6.09B |
| Total equity | $6.74B | $5.90B | -$327.0M | $5.30B | $5.39B | $4.87B | $4.75B | $4.57B | $4.83B | $4.25B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.56B | $1.75B | $1.77B | $1.31B | $1.49B | $921.0M | $1.02B | $1.09B | $889.0M | $793.0M |
| Depreciation and amortisation | $288.0M | $257.0M | $271.0M | $317.0M | $321.0M | $308.0M | $238.0M | $210.0M | $212.0M | $246.0M |
| Stock-based compensation | $128.0M | $129.0M | $111.0M | $125.0M | $110.0M | $83.0M | $72.0M | $70.0M | $60.0M | $58.0M |
| Capital expenditure | $407.0M | $378.0M | $298.0M | $291.0M | $188.0M | $119.0M | $155.0M | $177.0M | $176.0M | $139.0M |
| Investing cash flow | -$394.0M | -$1.26B | -$310.0M | -$338.0M | -$749.0M | -$147.0M | -$1.59B | -$705.0M | -$304.0M | -$238.0M |
| Financing cash flow | -$715.0M | -$752.0M | -$930.0M | -$1.37B | -$696.0M | -$717.0M | -$299.0M | -$797.0M | -$202.0M | -$268.0M |
| Dividends paid | $282.0M | $274.0M | $265.0M | $250.0M | $236.0M | $222.0M | $206.0M | $191.0M | $170.0M | $150.0M |
| Buybacks | $425.0M | $1.15B | $575.0M | $1.14B | $788.0M | $469.0M | $723.0M | $422.0M | $194.0M | $434.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001090872-25-000087.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |
| TXG | 10x Genomics, Inc. | $8.14B | — | 5.2% |